Related Experiment Video
Updated: Jan 28, 2026
Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
Pharmacologic approaches to the treatment of atherosclerotic arterial obstruction
1Service de Médecine Vasculaire, Hôpital Broussais, Paris, France.
Insights
Medical treatments target atherosclerosis at three stages: preventing plaque development, managing existing plaques, and treating ischemia. Controlling risk factors and plaque instability are key for effective prevention and intervention.
Area of Science:
- Cardiovascular Medicine
- Medical Research
- Pathophysiology
Background:
- Atherosclerosis progresses through distinct stages, offering multiple therapeutic intervention points.
- Established risk factors like hypertension, hyperlipidemia, and diabetes significantly influence atherosclerosis development and progression.
- Current prevention strategies focus on managing these risk factors, yielding benefits particularly in secondary prevention.
Purpose of the Study:
- To outline the therapeutic opportunities across the natural history of atherosclerosis.
- To highlight the importance of early and aggressive risk factor control for improved prophylaxis.
- To discuss interventions targeting plaque stability, thrombosis, and arterial remodeling for clinical manifestations.
Main Methods:
- Review of current medical treatments and prevention strategies for atherosclerosis.
- Analysis of the role of established and emerging risk factors.
- Exploration of interventions aimed at plaque progression, clinical manifestation, and ischemic complications.
Main Results:
- Medical interventions can target plaque development, progression, and clinical consequences of atherosclerosis.
- Improved control of risk factors and addressing new determinants can enhance preventive efficacy.
- Treatments can mitigate plaque-induced arterial obstruction by reducing thrombosis and improving plaque stability.
- Palliative treatments for ischemia focus on improving energy supply and exploring collateral channel enhancement.
Conclusions:
- Atherosclerosis management requires a multi-faceted approach targeting different stages of the disease.
- Enhanced risk factor modification and novel therapeutic strategies hold promise for more effective atherosclerosis prevention and treatment.
- Interventions to stabilize plaques and improve collateral circulation are crucial for managing clinical atherosclerosis.
Abstract:
Three consecutive periods in the natural history of atherosclerosis are amenable to medical treatment. Plaque development is the main target of prevention, which also aims at slowing the progression of already existing plaques. The control of several established risk factors (high blood cholesterol, high blood pressure, diabetes mellitus, tobacco smoking) has already yielded encouraging benefits, especially in the field of secondary prevention. More efficient prophylaxis is to be expected, either from the further improved control of these classic risk factors with earlier, stronger, and longer interventions or from the correction of newly established causal determinants of atherosclerosis. A plaque manifests itself clinically through progressive or abrupt obstruction of the arterial lumen, which can be avoided or retarded by interventions aimed at reducing thrombosis, at controlling plaque instability (the major cause of thrombosis), and at enhancing arterial remodeling (which allows compensatory enlargement of the arterial lumen). When ischemia has occurred, a third wave of palliative treatments aims at improving energy supply to the organ with compromised vascularization. Classic treatments reduce oxygen consumption or improve oxygen extraction by ischemic tissues. In addition, the design of drugs to enhance the development of collateral channels appears to be promising therapeutic approach.
More Related Videos
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
03:51Author Spotlight: Advanced Treatment of Seminal Duct Blockage Employing Endoscopy-Mediated Semen Channel Refluviation
Published on: December 8, 2023
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:28Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...